OncoHost Presents New Research on TKI Sensitivity in Metastatic Renal Cell Carcinoma

BINYAMINA, Israel and CARY, N.C., Oct. 26, 2026 /CourierPR/ -- OncoHost, a technology company based in Binyamina, Israel, and Cary, North Carolina, presented groundbreaking research at the European Society for Medical Oncology (ESMO) 2026 Congress, which took place from October 23 to 27 in Madrid, Spain.

Presented by Liliana Ascione, the poster was displayed at the Renal Cancer session in Hall 5, with the session number 3599P. The research focuses on a model that uses pretreatment plasma proteomics to classify patients with mRCC as TKI-Positive or TKI-Negative, thereby indicating which patients are more likely to benefit from a first-line combination therapy of immunotherapy and a tyrosine kinase inhibitor (TKI) versus dual immunotherapy.

The model, developed through a collaboration between OncoHost and Dana-Farber Cancer Institute, has been validated in 119 patients and independently confirmed in an additional 59 patients. According to Wenxin Xu, an oncologist and principal investigator at Dana-Farber Cancer Institute, the model has shown significant benefits. Patients with a TKI-Positive result had significantly longer overall survival on ICI-TKI combination therapy compared to dual immunotherapy, with a hazard ratio of 0.14 and a p-value of 0.003. The treatment-by-model interaction was also significant, with a p-value of 0.003, suggesting the model's potential to inform treatment selection.

New analysis presented at ESMO connects the model's predictive proteins to angiogenesis, inflammation, and other biological processes relevant to TKI sensitivity and resistance. Of the 169 core predictive proteins, 82 were associated with angiogenesis and vascular remodeling, including key components of the VEGF signaling pathway. Additional proteins were linked to VEGF-independent angiogenesis, inflammation, tumor plasticity, and extracellular matrix remodeling, highlighting the complexity of TKI sensitivity and resistance.

Protein origin analyses suggested that the proteomic signature reflects biological contributions from tumor cells, immune cells, and host stromal compartments. The model proteins also overlapped with previously described angiogenic molecular programs in RCC, providing a biologically coherent explanation for the model's association with TKI outcomes. The findings suggest that the plasma signature reflects multiple aspects of treatment sensitivity and resistance, extending beyond a single angiogenic pathway.

OncoHost's proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC® test, initially developed for non-small cell lung cancer (NSCLC), has shown significant clinical utility by offering physicians crucial guidance on the optimal treatment plan for each individual patient, with a notable effect on overall survival.

Led by an experienced team of entrepreneurs and industry experts, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage. With a large-scale prospective clinical trial involving over 40 sites and 1,700 patients recruited worldwide, the company is poised to continue advancing its innovative approach to precision medicine.